Market Overview
The global organ on chip market is valued at US$ 10.85 Mn in 2021 and is expected to grow at a CAGR of 31.2% over the forecast period to reach a US$ 31.85 Mn by 2029.
With the need for therapeutic treatment and diagnosis of chronic disease, the global Organ on Chip market has multiple advantages to edge on other treatment procedures
Market Dynamics
Additional factors backed-up for the growth for organ on chip market are governments funds and research grants, high focus on improved drug screening and growing applications of organ-on chip at developed nations such as North America, dominated by the U.S.
Drivers
- Government Funds and Research Grants
- High Focus on Improved Drug Screening and growing applications of organ-on chip
- Growing demand for kidney and lung organ on chip devices
Restraints
- Complexity in Device Fabrication
- High Cost of Devices
Download free sample: https://www.datamintelligence.com/download-sample/organ-on-chip-market
Market Segmentation
By Model Type, Lung-on-chip segment accounted for the largest market share in 2019 of about 26.1% which is estimated to increase to 26.3% by 2029
The lung on chip is one of the most commercially used organ model in the US. It occupied a share of approximately 15% of the total OOC market in 2017. Lung-on-chip organ models are designed using the human lung and blood vessel cells. It acts as a multifunctional model that has the potential to emulate key structural, functional and mechanical properties of the human alveolar-capillary interface. Two of the key competitors offering lung on chip models include – Emulate and AlveoliX AG.
By End-User, pharmaceutical companies are dominating the organ-on-chip market globally with a value of about US$ 6.68 Mn in 2019 which is expected to grow at a CAGR of 17.9% during the forecast period (2021-2029).
The organ on chip market by research organizations is estimated to reach a market value of US$ 8.6 million by 2026 from an initial market value of US$ 2.7 million in 2018 with the market growing at a CAGR of 15.3% in the forecasted period.
Geographical Segmentation
The North America organ-on-chip market is valued at USD 3.93 Mn in 2018 and is estimated to grow at a CAGR of 18.5% over the forecast period to reach a USD 15.07 by 2029.
The growth of the North America organ on-chips market is driven by surge in adoption of organ-on-chips over 2D and 3D cell cultures. Furthermore, rise in demand for OOCs in drug screening, especially in the U.S., and increase in number of key players of OOCs in North America are expected to fuel the growth of the market in the coming years.
The U.S. holds 75.8% of market share in 2018, and is expected to increase by 81.2% by 2026, for global organ-on-chip market.
On April 11, 2017, FDA announced a multi-year research and development agreement with a company called Emulate Inc. to test the company’s “Organs-on-Chips” technology in laboratories at the agency’s Centre for Food Safety and Applied Nutrition.
Competitive Landscape
The market players are adopting various key strategies such as collaborations, product launches, mergers & acquisitions, partnerships to expand their business contributing to the growth of the organ-on-chip market. For instance,
- In July 2019, InSphero AG launched a 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The platform has been precisely engineered to include all the human liver cell types and inducers necessary to replicate progression of NASH in patients, from fatty liver (steatosis) to inflammation (NASH) and scarring (fibrosis) of the liver.
- In July 2019, the new study of AxoSim’s Nerve-on-a-Chip technology showed that the platform accurately provides key physiological readouts that could help speed the development of drugs to treat neurological disorders. The study also shows that Nerve-on-a-Chip technology is the first all-human in vitro model that can measure critical factors that were formerly only available using live animal models. These include robust axonal outgrowth, myelination of human stem cell-derived neurons by primary human Schwann cells, and evaluation of nerve conduction velocity, according to the New Orleans-based company.
- In February 2018, Roche and Takeda have formed partnerships with Emulate, the biotech start-up behind organs-on-a-chip to use organ-chip technology in their R&D programmes. Emulate and Roche have formed a three-year partnership to use organ-chips for testing the efficacy and safety of new antibody therapeutics and combination therapies.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
